<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606628</url>
  </required_header>
  <id_info>
    <org_study_id>2020/95084/REK Sør-Øst</org_study_id>
    <nct_id>NCT04606628</nct_id>
  </id_info>
  <brief_title>Optimal Value Increase of Egg Products</brief_title>
  <acronym>OPTIEgg</acronym>
  <official_title>OPTIEgg- Optimal Value Increase of Egg Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nofima</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nortuna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orkla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danægg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to evaluate daily intake of eggshell membrane taken as supplement&#xD;
      (capsule), will reduce markers of inflammation in older people.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a randomized double-blinded controlled trial and is considered as a pilot study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>One of the employees will distribute the capsules and know which of the group is placebo and intervention. Everyone else involved in the project will be blinded for this knowledge.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma levels of inflammatory markers</measure>
    <time_frame>Measured at baseline and after 4 weeks (end of study)</time_frame>
    <description>concentration of C-reactive protein (CRP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma levels of inflammatory markers</measure>
    <time_frame>Measured at baseline and after 4 weeks (end of study)</time_frame>
    <description>concentration of Interleukin-6 (IL-6)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in body composition - measured by Bioimpedance (BIA)</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>fat free mass (% and kg), fatt mass (% and in kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>Measured by grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in markers related to lipid metabolism</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>Blood concentrations of e.g. triglycerides, total-, LDL- and HDL- cholesterol, free fatty acids and lipoprotein subclasses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood mononuclear cell (PBMC) gene expression</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>mRNA levels of of genes involved in lipid metabolism and inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota composition (optional)</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>Consenctration of faecal short-chain fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota composition (optional)</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>bacteria type and diversity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in satiety hormones</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>e.g. concentration of serum ghrelin, amylin, leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in metabolome plasma profile</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>concentration of amino acids in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in metabolome plasma profile</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>concentration of low molecular molecules in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>Weight (kg) measured by digital scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body mass index (BMI)</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>Measured as body weight in kg/height in meter2 ( kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physical performance</measure>
    <time_frame>Measured at baseline and after 4 weeks</time_frame>
    <description>Short Physical Performance Battery (SPPB) test (includes balance test, chair test (sit to stand) and walk test)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <condition>Inflammation</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume 2 capsules containing eggshell membrane(ESM) with breakfast every day in 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume 2 capsules with no bioactive substance (placebo) with breakfast every day in 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eggshell membrane (ESM)</intervention_name>
    <description>The intervention group will consume two capsules containing (in total) 500mg ESM with breakfast every day in 4 weeks.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo group will consume two placebo capsules (Cellulose) with breakfast every day in 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The study will include home-dwelling men and women ≥ 70 years. All subjects have to be in a&#xD;
        good enough condition to meet up at the Department of Nutrition, University of Oslo at two&#xD;
        occasions during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CRP &gt;10 mg/L&#xD;
&#xD;
          -  Egg allergy&#xD;
&#xD;
          -  Use of medication affecting inflammation&#xD;
&#xD;
          -  Unstable use of medication or supplements last 3 months&#xD;
&#xD;
          -  Unwilling to keep the physical activity level, habitual dietary intake, tobacco use&#xD;
             and weight stable during the study period&#xD;
&#xD;
          -  Severe illness last 3 months&#xD;
&#xD;
          -  Unwilling to perform physical tests&#xD;
&#xD;
          -  Eligibility&#xD;
&#xD;
          -  Diabetes type I or II, HbA1c ≥ 6.5 %&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stine M Ulven, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitetet i Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stine M Ulven, PhD</last_name>
    <phone>+47 2284 0208</phone>
    <email>smulven@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Oslo</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stine M Ulven, PhD</last_name>
      <phone>+47 2284 0208</phone>
      <email>smulven@medisin.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Stine Marie Ulven</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Eggshell membrane</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Old volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

